KEKurt Eng

Kurt Eng

*This is an algorithmically generated author record based on publicly available information.

Kurt Eng has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data: Figure S1-3 and Table S1-S5 from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

    by Adnan O. Abu-Yousif, Donna Cvet, Melissa Gallery, Bret M. Bannerman, Michelle L. Ganno, Michael D. Smith, Katharine C. Lai, Thomas A. Keating, Bradley Stringer, Afrand Kamali, et al.

    Supplemental Figure 1: heavy and light chain sequences for 5F9, the human IgG1 monoclonal antibody (mAb) targeting the extracellular domain of GCC as described previously Supplemental Figure 2: Characterization of TAK-164 and chKTI-DGN549 by A) SDS PAGE gel and B) by Liquid chromatography-mass spectrometry (LC-MS) Supplemental Figure 3: In vivo activity of TAK-164 in PHTXM-46C Supplemental Table 1: Growth rate inhibition following treatment with TAK-164 and B) chKTI-ADC in PHTX and cell derived xenograft models Supplemental Table 2: Growth Rate Inhibition and associated statistics for HEK293 GCC#2 Supplemental Table 3: Growth Rate Inhibition and associated statistics for PHTX-09C Supplemental Table 4: Growth Rate Inhibition and associated statistics for PHTX-17C Supplemental Table 5: Growth Rate Inhibition and associated statistics for PHTX-11C

  • Open Access

    Data from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

    by Adnan O. Abu-Yousif, Donna Cvet, Melissa Gallery, Bret M. Bannerman, Michelle L. Ganno, Michael D. Smith, Katharine C. Lai, Thomas A. Keating, Bradley Stringer, Afrand Kamali, et al.

    Guanylyl cyclase C (GCC) is a unique therapeutic target with expression restricted to the apical side of epithelial cell tight junctions thought to be only accessible by intravenously administered agents on malignant tissues where GCC expression is aberrant. In this study, we sought to evaluate the therapeutic potential of a second-generation investigational antibody–dug conjugate (ADC), TAK-164, comprised of a human anti-GCC mAb conjugated via a peptide linker to the highly cytotoxic DNA alkylator, DGN549. The in vitro binding, payload release, and in vitro activity of TAK-164 was characterized motivating in vivo evaluation. The efficacy of TAK-164 and the relationship to exposure, pharmacodynamic marker activation, and biodistribution was evaluated in xenograft models and primary human tumor xenograft (PHTX) models. We demonstrate TAK-164 selectively binds to, is internalized by, and has potent cytotoxic effects against GCC-expressing cells in vitro. A single intravenous administration of TAK-164 (0.76 mg/kg) resulted in significant growth rate inhibition in PHTX models of metastatic colorectal cancer. Furthermore, imaging studies characterized TAK-164 uptake and activity and showed positive relationships between GCC expression and tumor uptake which correlated with antitumor activity. Collectively, our data suggest that TAK-164 is highly active in multiple GCC-positive tumors including those refractory to TAK-264, a GCC-targeted auristatin ADC. A strong relationship between uptake of 89Zr-labeled TAK-164, levels of GCC expression and, most notably, response to TAK-164 therapy in GCC-expressing xenografts and PHTX models. These data supported the clinical development of TAK-164 as part of a first-in-human clinical trial (NCT03449030).

  • Open Access

    Data from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

    by Adnan O. Abu-Yousif, Donna Cvet, Melissa Gallery, Bret M. Bannerman, Michelle L. Ganno, Michael D. Smith, Katharine C. Lai, Thomas A. Keating, Bradley Stringer, Afrand Kamali, et al.

    Guanylyl cyclase C (GCC) is a unique therapeutic target with expression restricted to the apical side of epithelial cell tight junctions thought to be only accessible by intravenously administered agents on malignant tissues where GCC expression is aberrant. In this study, we sought to evaluate the therapeutic potential of a second-generation investigational antibody–dug conjugate (ADC), TAK-164, comprised of a human anti-GCC mAb conjugated via a peptide linker to the highly cytotoxic DNA alkylator, DGN549. The in vitro binding, payload release, and in vitro activity of TAK-164 was characterized motivating in vivo evaluation. The efficacy of TAK-164 and the relationship to exposure, pharmacodynamic marker activation, and biodistribution was evaluated in xenograft models and primary human tumor xenograft (PHTX) models. We demonstrate TAK-164 selectively binds to, is internalized by, and has potent cytotoxic effects against GCC-expressing cells in vitro. A single intravenous administration of TAK-164 (0.76 mg/kg) resulted in significant growth rate inhibition in PHTX models of metastatic colorectal cancer. Furthermore, imaging studies characterized TAK-164 uptake and activity and showed positive relationships between GCC expression and tumor uptake which correlated with antitumor activity. Collectively, our data suggest that TAK-164 is highly active in multiple GCC-positive tumors including those refractory to TAK-264, a GCC-targeted auristatin ADC. A strong relationship between uptake of 89Zr-labeled TAK-164, levels of GCC expression and, most notably, response to TAK-164 therapy in GCC-expressing xenografts and PHTX models. These data supported the clinical development of TAK-164 as part of a first-in-human clinical trial (NCT03449030).

  • Open Access

    Supplementary Data: Figure S1-3 and Table S1-S5 from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

    by Adnan O. Abu-Yousif, Donna Cvet, Melissa Gallery, Bret M. Bannerman, Michelle L. Ganno, Michael D. Smith, Katharine C. Lai, Thomas A. Keating, Bradley Stringer, Afrand Kamali, et al.

    Supplemental Figure 1: heavy and light chain sequences for 5F9, the human IgG1 monoclonal antibody (mAb) targeting the extracellular domain of GCC as described previously Supplemental Figure 2: Characterization of TAK-164 and chKTI-DGN549 by A) SDS PAGE gel and B) by Liquid chromatography-mass spectrometry (LC-MS) Supplemental Figure 3: In vivo activity of TAK-164 in PHTXM-46C Supplemental Table 1: Growth rate inhibition following treatment with TAK-164 and B) chKTI-ADC in PHTX and cell derived xenograft models Supplemental Table 2: Growth Rate Inhibition and associated statistics for HEK293 GCC#2 Supplemental Table 3: Growth Rate Inhibition and associated statistics for PHTX-09C Supplemental Table 4: Growth Rate Inhibition and associated statistics for PHTX-17C Supplemental Table 5: Growth Rate Inhibition and associated statistics for PHTX-11C

  • Open Access

    A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery

    by Kenichi Iwai, Tadahiro Nambu, Yukie Kashima, Jie Yu, Kurt Eng, Kazumasa Miyamoto, Kazuyo Kakoi, Masamitsu Gotou, Toshiyuki Takeuchi, Akifumi Kogame, et al.

    Potential combination partners of a CDC7 inhibitor TAK-931 were identified to guide its clinical development strategy.


  • Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

    by Adnan O. Abu-Yousif, Donna Cvet, Melissa Gallery, Bret M. Bannerman, Michelle L. Ganno, Michael D. Smith, Katharine C. Lai, Thomas A. Keating, Bradley Stringer, Afrand Kamali, et al.

    Guanylyl cyclase C (GCC) is a unique therapeutic target with expression restricted to the apical side of epithelial cell tight junctions thought to be only accessible by intravenously administered agents on malignant tissues where GCC expression is aberrant. In this study, we sought to evaluate the therapeutic potential of a second-generation investigational antibody–dug conjugate (ADC), TAK-164, comprised of a human anti-GCC mAb conjugated via a peptide linker to the highly cytotoxic DNA alkylator, DGN549. The in vitro binding, payload release, and in vitro activity of TAK-164 was characterized motivating in vivo evaluation. The efficacy of TAK-164 and the relationship to exposure, pharmacodynamic marker activation, and biodistribution was evaluated in xenograft models and primary human tumor xenograft (PHTX) models. We demonstrate TAK-164 selectively binds to, is internalized by, and has potent cytotoxic effects against GCC-expressing cells in vitro. A single intravenous administration of TAK-164 (0.76 mg/kg) resulted in significant growth rate inhibition in PHTX models of metastatic colorectal cancer. Furthermore, imaging studies characterized TAK-164 uptake and activity and showed positive relationships between GCC expression and tumor uptake which correlated with antitumor activity. Collectively, our data suggest that TAK-164 is highly active in multiple GCC-positive tumors including those refractory to TAK-264, a GCC-targeted auristatin ADC. A strong relationship between uptake of 89Zr-labeled TAK-164, levels of GCC expression and, most notably, response to TAK-164 therapy in GCC-expressing xenografts and PHTX models. These data supported the clinical development of TAK-164 as part of a first-in-human clinical trial (NCT03449030).


  • A bilayer small diameter in vitro vascular model for evaluation of drug induced vascular injury

    by David M. Hoganson, Eric B. Finkelstein, Gwen E. Owens, James C. Hsiao, Kurt Y. Eng, Katherine M. Kulig, Ernest S. Kim, Tatiana Kniazeva, Irina Pomerantseva, Craig M. Neville, et al.

    In pre-clinical safety studies, drug-induced vascular injury (DIVI) is defined as an adverse response to a drug characterized by degenerative and hyperplastic changes of endothelial cells and vascular smooth muscle cells. Inflammation may also be seen, along with extravasation of red blood cells into the smooth muscle layer (i.e., hemorrhage). Drugs that cause DIVI are often discontinued from development after considerable cost has occurred. An in vitro vascular model has been developed using endothelial and smooth muscle cells in co-culture across a porous membrane mimicking the internal elastic lamina. Arterial flow rates of perfusion media within the endothelial chamber of the model induce physiologic endothelial cell alignment. Pilot testing with a drug known to cause DIVI induced extravasation of red blood cells into the smooth muscle layer in all devices with no extravasation seen in control devices. This engineered vascular model offers the potential to evaluate candidate drugs for DIVI early in the discovery process. The physiologic flow within the co-culture model also makes it candidate for a wide variety of vascular biology investigations.